Keros Therapeutics Presents Clinical Data from its KER-050 and KER-… Keros Therapeutics Hosts Conference Call and Webcast Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. The event will provide an opportunity for investors, analysts, and the general public to learn more about the latest clinical…
The Investigation of Chegg, Inc. by Kaskela Law LLC Introduction On December 12, 2022, Kaskela Law LLC announced that it is investigating Chegg, Inc. (“Chegg” or the “Company”) (NYSE: CHGG) on behalf of the Company’s long-term stockholders. The investigation stems from a recent securities fraud complaint filed against Chegg on behalf of investors who purchased…
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp., a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it has reached a comprehensive Settlement and…
Market movers: European stock exchanges closed the week mixed and with much uncertainty as they await this week’s central bank decisions. In addition, the publication in the early afternoon of producer prices in the United States (on a monthly basis at +0.3%, expectations for +0.2%) also raised fears for continued tightening of interest rates. Following…
TransUnion (TRU) Shareholder Notice: Contact Robbins LLP for Information About our Investigation San Diego, Dec. 12, 2022 (GLOBE NEWSWIRE) – Shareholder rights law firm Robbins LLP is currently conducting an investigation into TransUnion (NYSE: TRU) to determine whether certain officers and directors of the company have violated securities laws and breached fiduciary duties to shareholders….
The Impact of Voyager Digital Holdings Investor Losses Introduction Recently, Rosen Law Firm has issued a reminder to purchasers of Voyager Earn Accounts and VGX tokens about potential losses incurred between January 1, 2020 and November 9, 2022. This news has caused a stir among investors and raised questions about the security and reliability of…
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting… Exciting Advances in Cell Therapy Have you heard the latest buzz from the ASH Annual Meeting? Senti Bio presented groundbreaking preclinical data on their innovative off-the-shelf CAR-NK cell therapy candidate, SENTI-202. This therapy is engineered with a logic-gated…
Agios Pharmaceuticals Presents Updated PYRUKYND® Data Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Agios Pharmaceuticals, Inc. is currently conducting Phase 3 ENERGIZE and ENERGIZE-T studies to evaluate the effectiveness of PYRUKYND® in adults with non-transfusion-dependent and transfusion-dependent α- or β-Thalassemia, respectively. This innovative drug has shown promise in improving outcomes for patients with these…
